

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA BIOTECH SERVICES HOLDINGS LIMITED

中國生物科技服務控股有限公司

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)

(Stock code: 8037)

POSITIVE PROFIT ALERT

This announcement is made by China Biotech Services Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 17.10(2)(a) of the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited (the “**GEM Listing Rules**”) and the Inside Information Provisions (as defined under the GEM Listing Rules).

The board (the “**Board**”) of directors (“**Directors**”) of the Company wishes to inform the shareholders of the Company (“**Shareholders**”) and potential investors that based on the latest information currently available to the Board including the unaudited consolidated management accounts of the Group for the three months ended 31 March 2022 (“**2022 Q1 Period**”), the Group is expected to record a net profit attributable to the owners of the Company (“**Net Profit**”) of not less than HK\$34,000,000 for the 2022 Q1 Period as compared with that of approximately HK\$1,819,000 recorded for the corresponding period in 2021. It represented an increase of Net Profit for more than 17.69 times on a year-on-year basis. The Board considers that such an increase of the Net Profit for 2022 Q1 Period was mainly attributable to the robust demands for rapid antigen test kits and COVID-19 testing services during the period due to the raging fifth wave of COVID-19 pandemic.

The information contained in this announcement is only based on the preliminary assessment by the Board with reference to the latest information currently available to the Board which has not been reviewed nor audited by the auditors of the Company and may be subject to change. The Group is still in the process of finalising the unaudited condensed consolidated first quarterly results for the 2022 Q1 Period (“**First Quarterly Results**”). The actual figures to be announced in the First Quarterly Results may be different from those disclosed in this announcement. Shareholders and potential investors of the Company are advised to read the First Quarterly Results carefully, which are expected to be announced by mid of May 2022.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
China Biotech Services Holdings Limited
Liu Xiaolin
Chairman and Executive Director

Hong Kong, 5 May 2022

As at the date of this announcement, the board of Directors comprises four executive Directors, namely, Mr. Liu Xiaolin (Chairman), Mr. He Xun, Mr. Huang Song and Mr. Wang Zheng; and three independent non-executive Directors, namely, Mr. Yan Guoxiang, Dr. Ho Ivan Chun Kit and Mr. Qian Hongji.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive; and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Listed Company Announcements” page of the GEM website at www.hkgem.com for at least 7 days from the date of its publication and on the website of the Company at www.cbshhk.com.